SMYD3 and hepatocellular carcinoma: In vivo, SMYD3 overexpression promotes disease progression in pancreatic cancer (PC) [2], lung cancer [3], hepatocellular carcinoma (HCC), colorectal cancer (CRC) [4], gastric cancer (GC) [5], breast cancer [6], esophageal squamous cell carcinoma [7], and ovarian cancer [8].